| |
| | PRESS RELEASE Early Virologic Response (EVR) to Peg-Intron(R) Individualized Weight-Based Therapy for Hepatitis C ... (Site not responding. Last check: 2007-10-10) |
 | | "A 12-week EVR provides patients and physicians with an early marker and, for the majority of patients who attain EVR, can help encourage patients to complete therapy," said Gary L. Davis, M.D., director of the division of hepatology, Baylor University Medical Center, Dallas, and lead author of the paper. |
 | | As noted in the paper, 74 percent of patients demonstrated an EVR following 12 weeks of individualized, weight-based dosing of PEG-INTRON (1.5 ug/kg/week) and REBETOL (800 mg/day) combination therapy and, of those patients, 72 percent (positive predictive value) went on to achieve a sustained virologic response (SVR) after a full, 48-week course of treatment. |
 | | EVR is defined as at least a 99 percent (2 log10) reduction in hepatitis C virus (HCV) load at week 12 of therapy. |
| www.marketwire.com /mw/release_html_b1?release_id=58641 (1330 words) |
|